-
Product Insights
NewNet Present Value Model: MoonLake Immunotherapeutics’s Sonelokimab
Empower your strategies with our Net Present Value Model: MoonLake Immunotherapeutics's Sonelokimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Insmed Inc’s Treprostinil Palmitil
Empower your strategies with our Net Present Value Model: Insmed Inc's Treprostinil Palmitil report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sonelokimab in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sonelokimab in Psoriatic Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sonelokimab in Psoriatic Arthritis Drug Details: Sonelokimab (M-1095) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sonelokimab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sonelokimab in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sonelokimab in Hidradenitis Suppurativa Drug Details: Sonelokimab (M-1095) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sonelokimab in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sonelokimab in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sonelokimab in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: Sonelokimab (M-1095)...
-
Product Insights
NewHidradenitis Suppurativa – Drugs In Development, 2024
Empower your strategies with our Hidradenitis Suppurativa – Drugs In Development, 2024 report and make more profitable business decisions. Hidradenitis suppurativa (HS) is a chronic skin condition that features pea- to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop in areas where skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts. The Hidradenitis Suppurativa drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewPsoriatic Arthritis – Drugs In Development, 2024
Empower your strategies with our Psoriatic Arthritis – Drugs In Development, 2024 report and make more profitable business decisions. Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain, and lower back pain. Risk factors include age, family history, and psoriasis. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and surgery. The Psoriatic Arthritis drugs in development market research report provide comprehensive information on the therapeutics under development for Psoriatic...
-
Product Insights
NewAxial Spondyloarthritis – Drugs In Development, 2024
Empower your strategies with our Axial Spondyloarthritis – Drugs In Development, 2024 report and make more profitable business decisions. Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available. The Axial Spondyloarthritis drugs in development market research report provide comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target,...
-
Product Insights
NewAnkylosing Spondylitis (Bekhterev’s Disease) – Drugs In Development, 2024
Empower your strategies with our Ankylosing Spondylitis (Bekhterev's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture. The Ankylosing Spondylitis (Bekhterev's Disease) drugs...